id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-N-0313-0009,FDA,FDA-2003-N-0313,Labeling Comprehension Study Toll-Free Number for Reporting Adverse Events on Labeling for Human Drug Products,Supporting & Related Material,Background Material,2008-10-28T04:00:00Z,2008,10,,,2016-02-05T18:05:05Z,,0,0,090000648078103d
FDA-2003-N-0313-0008,FDA,FDA-2003-N-0313,Toll-Free Number for Reporting Adverse Events on Labeling for Human Drug Products; Final Rule,Rule,Final Rule,2008-10-28T04:00:00Z,2008,10,2008-10-28T04:00:00Z,,2016-02-09T17:49:24Z,E8-25670,0,0,0900006480780764
FDA-2003-N-0313-0007,FDA,FDA-2003-N-0313,Outreach Letter from FDA (Office of Federal State Relations),Other,Letter(s),2008-07-31T04:00:00Z,2008,7,2008-07-31T04:00:00Z,,2016-02-09T17:48:29Z,,0,0,09000064806a4e29
FDA-2003-N-0313-0006,FDA,FDA-2003-N-0313,Toll-Free Number for Reporting Adverse Events on Labeling for Human Drug Products; Interim Final Rule,Rule,Interim Final Rule,2008-01-03T05:00:00Z,2008,1,2008-01-02T05:00:00Z,,2016-02-09T17:44:40Z,,0,0,0900006480494f76